Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study

References

• Klamroth R. Treatment of haemophilia A with recombinant antihaemophilic factor VIII products. Eur Haematol Rev 2007;1:11-15
   Google Scholar
• Fast Facts About Bleeding Disorders. National Hemophilia Foundation. Available at: https://www.hemophilia.org/About-Us/Fast-Facts [Last accessed 1 January 2016]
   Google Scholar
• Hemophilia A. National Organization for Rare Disorders. Available at: https://rarediseases.org/rare-diseases/hemophilia-a/ [Last accessed 1 January 2016]
   Google Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015;125:2038-44
   PubMed Web of Science ®Google Scholar
• MASAC Recommendation Concerning Prophylaxis. National Hemophilia Foundation. Available at: https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis [Last accessed 1 January 2016]
   Google Scholar
• The World Federation of Hemophilia’s Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders. Available at: http://www1.wfh.org/publications/files/pdf-1274.pdf [Last accessed 21 December 2015]
   Google Scholar
• Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010;8:292-6
   PubMed Web of Science ®Google Scholar
• Qu Y, Nie X, Yang Z, et al. The prevalence of hemophilia in mainland China: a systematic review and meta-analysis. Southeast Asian J Trop Med Public Health 2014;45:455-66
   PubMed Web of Science ®Google Scholar
• Aygoren-Pursun E, Scharrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost 1997;78:1352-6
   PubMed Web of Science ®Google Scholar
• Yoshioka A, Shima M, Fukutake K, et al. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001;7:242-9
   PubMed Web of Science ®Google Scholar
• Giangrande PL; Kogenate Bayer Study Group. Safety and efficacy of Kogenate Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002;8(Suppl 2):19-22
   PubMed Web of Science ®Google Scholar
• Scharrer I; Kogenate Bayer Study Group. Experience with Kogenate Bayer in surgical procedures. Haemophilia 2002;8(Suppl 2):15-18
   PubMed Web of Science ®Google Scholar
• Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005;93:457-67
   PubMed Web of Science ®Google Scholar
• Yoshioka A, Fukutake K, Takamatsu J. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data. Int J Hematol 2006;84:158-65
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004;10:428-37
   PubMed Web of Science ®Google Scholar
• Brand B, Gruppo R, Wynn TT, et al. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients. Haemophilia 2016;22:e251-8
   PubMed Web of Science ®Google Scholar
• Stidl R, Fuchs S, Bossard M, et al. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates. Haemophilia 2016;22:54-64
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wu J, et al. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia 2007;13:351-6
   PubMed Web of Science ®Google Scholar
• Xin L, Jing WU, Ping S. Recombinant factor VIII for treatment of patients with hemophilia A in China. Chin J Thromb Hemost 2007;13:57-9
   Web of Science ®Google Scholar
• Lei Z, Liping J, Mengsu T. Efficacy of recombinant factor VIII in 16 hemophilia patients [in Chinese]. Chin J Pract Intern Med 2008;28:943-5
   Google Scholar
• Qing LW, Jing S, Hua SD. Efficacy and inhibitor generation of recombinant factor VIII in Chinese patients with hemophilia A [in Chinese]. Chin J Thromb Hemost 2008;14:257-60
   Google Scholar
• Dan L, Ming X, Xian Z. A preliminary study on treatment of joint bleeding in children with severe and moderate hemophilia A: low-dose short-course recombinant human factor concentration as secondary prophylaxis. West China Med J 2011;26:1136-8
   Google Scholar
• Wu R, Luke KH. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011;17:70-4
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:1935-9
   PubMed Web of Science ®Google Scholar
• Introductory Guide MedDRA Version 18.0. MedDra Web site. Available at: http://www.meddra.org/sites/default/files/guidance/file/intguide_18_0_english.pdf [Last accessed 1 January 2016]
   Google Scholar
• Common Terminology Criteria for Adverse Events v4.0 (CTCAE). National Institute of Health. Available at: https://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf [Last accessed 1 January 2016]
   Google Scholar
• Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Org 1995;73:691-701
   PubMed Web of Science ®Google Scholar
• Berntorp E. Guidelines on treatment of haemophilia in Sweden. Haemophilia 1998;4:425-6
   PubMed Web of Science ®Google Scholar
• Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010;8:83-9
   PubMed Web of Science ®Google Scholar
• Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993;328:453-9
   PubMed Web of Science ®Google Scholar
• Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994;83(9):2428-35
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Zimmermann R, Katsarou O, et al. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia 2015;21:171-9
   PubMed Web of Science ®Google Scholar
• Kavakli K, Yang R, Rusen L. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015;13:360-9
   PubMed Web of Science ®Google Scholar
• Tang L, Wu R, Sun J, et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 2013;19:27-34
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, fulllength, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015;126:1078-85
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014;123:317-25
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Ma AD, Klamroth R, et al. Joint bleeding patterns in patients treated prophylactically with an extended half-life, pegylated, full-length recombinant factor VIII (BAX 855). Blood 2015;126:2300
   Web of Science ®Google Scholar
• White GC, McMillan CW, Blatt PM, et al. Factor VIII inhibitors: a clinical overview. Am J Hematol 1982;13:335-42
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10:359-67
   PubMed Web of Science ®Google Scholar
• Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A. Haemophilia 2010;16:632-9
   PubMed Web of Science ®Google Scholar
• Ewenstein BM, Gomperts ED, Pearson S, O’Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004;10:491-8
   PubMed Web of Science ®Google Scholar
• Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus 2014;12(Suppl 1):S319-S29
   PubMed Web of Science ®Google Scholar
• Xi M, Makris M, Marcucci M, et al. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013;11:1655-62
   PubMed Web of Science ®Google Scholar
• Kempton CL. Inhibitors in previously treated patients: a review of the literature. Haemophilia 2010;16:61-5
   PubMed Web of Science ®Google Scholar